Peter Garcia
2023 - ALX ONCOLOGY HOLDINGS
In 2023, Peter Garcia earned a total compensation of $1.3M as Chief Financial Officer at ALX ONCOLOGY HOLDINGS, a 26% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $194,189 |
|---|---|
| Option Awards | $435,765 |
| Salary | $485,472 |
| Stock Awards | $187,520 |
| Total | $1,302,946 |
Garcia received $485.5K in salary, accounting for 37% of the total pay in 2023.
Garcia also received $194.2K in non-equity incentive plan, $435.8K in option awards and $187.5K in stock awards.
Rankings
In 2023, Peter Garcia's compensation ranked 850th out of 2,311 executives tracked by ExecPay. In other words, Garcia earned more than 63.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 850 out of 2,311 | 63rd |
Division Manufacturing | 495 out of 1,247 | 60th |
Major group Chemicals And Allied Products | 335 out of 705 | 53rd |
Industry group Drugs | 325 out of 676 | 52nd |
Industry Pharmaceutical Preparations | 225 out of 490 | 54th |
Source: SEC filing on April 22, 2024.
Garcia's colleagues
We found three more compensation records of executives who worked with Peter Garcia at ALX ONCOLOGY HOLDINGS in 2023.
News
ALX ONCOLOGY HOLDINGS CEO Jason Lettmann receives $4.9M in 2023
April 22, 2024
ALX ONCOLOGY HOLDINGS CEO Jaume Pons' 2022 pay falls 63% to $3.7M
April 24, 2023
PDL BioPharma CEO Dominique Monnet's 2019 pay jumps 168% to $6.7M
July 7, 2020
PDL BioPharma CEO John McLaughlin's 2018 pay rises 20% to $4.1M
April 30, 2019